Year-end Sale % OFF 
Abstract
Biologic therapies targeting aberrant immune responses in cutaneous and systemic autoimmune diseases have had a significant impact on reducing mortality and morbidity for conditions that could not be treated with conventional drugs. However, their systemic effects increase vulnerability to infections, malignancies, and development of secondary autoimmune complications, underscoring the need for localized, targeted delivery of biologics. The article by Ying-Chao et al. (2022) titled “A keratinocyte-tethered biologic enables location-precise treatment in mouse vitiligo” highlights the potential for using bispecific antibodies (BsAbs) as a novel method of localized drug delivery through tethering, where one of the two antibody specificities is used to target a structural surface protein to anchor the biologic within the tissue.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
